积极推进CCRC养老社区、城心养老公寓、康养旅居三大养老产品线布局落地，截至本报告期末，已累 计在15个城市布局19个机构养老项目，推出四款"随心居"旅居产品，研究探索居家养老服务建设，满足 客户多元养老需求，赋能保险主业发展。 8月27日，中国人寿发布2025年半年度报告。 截至本报告期末，总资产突破7万亿元，达7.29万亿元，净资产达5,355.99亿元，内含价值为1.48万亿 元。报告期内，总保费达5,250.88亿元，增速创近五年同期新高，上半年新业务价值达285.46亿元，实 现快速增长，规模、价值继续保持行业领先。实现归属于母公司股东的净利润409.31亿元，同比增长 6.9%。 2025年上半年，公司在大健康与大养老服务领域不断探索创新，稳步推进服务体系建设，打造全方位、 多层次的健康养老服务生态。 ...

Group 1 - Multiple regions in China are implementing supportive policies for the elderly care industry, including Guangzhou and Shaanxi, aiming to enhance the financial services for elderly care and establish a robust support system by 2035 [1][2] - Shenzhen has released implementation opinions focusing on pension finance, elderly service finance, and elderly industry finance, with 17 specific measures to create a high-quality elderly care model [2] - The aging population in China is projected to exceed 310 million by the end of 2024, creating significant opportunities for the elderly care industry, with a market size expected to reach approximately 106 trillion yuan by 2050 [2] Group 2 - As of May 14, 2023, over 40 stocks related to the elderly care industry in A-shares have seen an average price increase of 2.21% this year, with notable performers like Miaokelan and Haoyue Nursing rising over 40% [3] - Approximately half of the elderly care concept stocks have received increased leverage funding, with significant net purchases exceeding 100 million yuan for companies like Aier Eye Hospital and Heng Rui Medicine [3] - In Q1 2024, 17 elderly care concept stocks reported net profits exceeding 100 million yuan, with China Life Insurance leading at 28.802 billion yuan, reflecting a substantial year-on-year growth of 39.5% [3] Group 3 - Zhejiang Medicine and New Harmony achieved remarkable net profit growth of 273.08% and 116.18% respectively in Q1, indicating strong performance in the elderly care sector [4] - Among the high-performing stocks with net profits over 100 million yuan, 12 received ratings from at least five institutions, with projected profit growth for 2025, including predictions of 88.64% for Covestro and 18.62% for Hualan Biological [4]